New Delhi: Bharat Biotech on Sunday said its COVID-19 vaccine ‘Covaxin’ has been found to be effective against coronavirus strains found in India and the UK.
Citing a study published in peer-reviewed medical journal Clinical Infectious Diseases, the Hyderabad-based vaccine major noted that vaccination with Covaxin produced neutralising titres against all key emerging variants tested, including B.1.617 and B.1.1.7, first identified in India and the UK, respectively.
“Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants. Yet another feather in its cap,” Bharat Biotech co-founder and Joint Managing Director Suchitra Ella said in a tweet. She also tagged PMO India, Finance Minister Nirmala Sitharaman and Health Minister Harsh Vardhan, among others, in the tweet.
The study found a modest reduction in neutralisation by a factor of 1.95 against B.1.617 variant compared to vaccine variant D614G, Bharat Biotech noted.
Despite this reduction, neutralising titre levels with B.1.617 remain above levels expected to be protective, it added.
- 28,326 new COVID infections recorded in India, total tally at 3,36,52,745
- Meghalaya: Two minor girls kidnapped, rescued from Assam
- Centre to soon announce new cooperative policy: Amit Shah
- CBIC makes Aadhaar authentication mandatory for claiming GST refund
- Assam govt seeks Centre’s help in popularising traditional weaves
- ‘Kanyadaan’ an outdated ritual or important custom? Alia Bhatt’s ad sparks debate